EMA completes review of weight management drug Mysimba

• April 4 2025
• Pharmacovigilance
• 04 Apr 2025

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting 13-16 January 2025

• January 27 2025
• Medicines
• Pharmacovigilance
• 24 Jan 2025

Read more

Announcement from the European Medicines Agency following the CHMP_CMDh meeting in December 2024

• January 27 2025
• Pharmacovigilance
• 18 Dec 2024

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) Meeting 25-28 November 2024

• December 20 2024
• Pharmacovigilance
• Citizens
• Manufacturing
• Health professionals
• Other Bodies
• 04 Dec 2024

Using opioid medications with Mysimba may lead to serious side effects

• December 20 2024
• Pharmacovigilance
• Citizens
• Manufacturing
• Health professionals
• Other Bodies
• 26 Nov 2024

PRESS RELEASE REGARDING THE DISTRIBUTION OF EDUCATIONAL MATERIALS

• December 20 2024
• Pharmacovigilance
• Citizens
• Manufacturing
• Health professionals
• Other Bodies
• 01 Nov 2024

Key points of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting 30/9 -3/10/2024

• December 20 2024
• Pharmacovigilance
• Citizens
• Manufacturing
• Health professionals
• Other Bodies
• 18 Oct 2024

EMA launches review of safety data on finasteride and dutasteride regarding suicidal thoughts and behaviors

• December 20 2024
• Pharmacovigilance
• Citizens
• Manufacturing
• Health professionals
• Other Bodies
• 11 Oct 2024

Oxbryta: Withdrawal of marketing authorization from the EMA

• December 20 2024
• Pharmacovigilance
• Citizens
• Manufacturing
• Health professionals
• Other Bodies
• 27 Sep 2024

Key points from the PRAC meeting, 2-5 September 202

• December 20 2024
• Pharmacovigilance
• Citizens
• Manufacturing
• Health professionals
• Other Bodies
• 11 Sep 2024